MediciNova clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898MN-166Active not recruiting2027-04Estimated

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline of FVC (forced vital capacity) at 26 weeks. After: Measure: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks Measure: Percent Change in Forced Vital Capacity From Baseline to Week 26 Measure: Absolute Change From Baseline in Forced Vital Capacity (% Predicted) Measure: Relative Change From Baseline in Percent Predicted Forced Vital Capacity From Baseline to Week 26 Measure: Semiannual Rate of Decline of Disease Activity Based on Forced Vital Capacity.

Check registry source